The Original Peptide Supermarket South Africa Beware of copycat sites. The only genuine address is peptidesupermarket.co.za

Home › Research › What Does DAC Mean in CJC-1295?
Back to Guides

What Does DAC Mean in CJC-1295?

DAC means Drug Affinity Complex. In CJC-1295, it is the albumin-binding feature that gives the GHRH analogue its long-lasting research profile.

Published 29 Oct 2026 10 min read Reference-backed
All content is for educational and research reference purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Read our full disclosure.
What Does DAC Mean in CJC-1295?

What does DAC stand for in CJC-1295?

DAC stands for Drug Affinity Complex. In CJC-1295 with DAC, it describes the chemical feature engineered into the peptide so that it can bind to albumin in a long-lasting way. Albumin is the major carrier protein in blood, and albumin binding is one of the common strategies used in drug design to extend how long a molecule remains available in a biological system.

The full name used for this compound is Modified Growth Hormone Releasing Factor (1-29) with Drug Affinity Complex. It is a modified analogue of growth hormone-releasing hormone, often shortened to GHRH. The reason researchers care about the DAC part is simple: it changes the duration of GHRH activity. CJC-1295 DAC is studied for sustained growth hormone stimulation rather than a brief pulse.

Strictly speaking, the DAC is not a brand name or a quality grade. It is the albumin-binding design element that makes CJC-1295 with DAC pharmacologically different from shorter-acting modified GRF peptides.

This distinction matters because the peptide research market often uses confusing shorthand. You will see phrases such as CJC-1295 DAC, CJC-1295 with DAC, CJC-1295 no DAC, and modified GRF (1-29). They are not interchangeable descriptions, even when listings make them look similar.

How does the Drug Affinity Complex work?

The Drug Affinity Complex in CJC-1295 is designed to support covalent, long-lasting albumin binding. In practical research terms, albumin binding can protect a peptide from rapid clearance. Small peptides are usually vulnerable to enzymatic breakdown and renal filtration. Attaching them, directly or indirectly, to a large carrier protein changes that behaviour.

CJC-1295 still acts as a GHRH analogue. Its research interest comes from stimulation of the GHRH receptor pathway, which is upstream of growth hormone release. The DAC does not turn it into a different class of molecule. It changes exposure time.

That exposure difference is why CJC-1295 with DAC is usually discussed as a long-acting GHRH analogue. The intended research profile is sustained GH release and downstream increases in IGF-1 signalling markers. The supplied reference data describes its use case as growth hormone stimulation, with studied or proposed outcomes including lean mass change, fat loss endpoints, recovery and tissue repair markers, energy-related measures, and sustained GH release.

Is CJC-1295 with DAC the same as CJC-1295 without DAC?

This is the main naming trap. In a strict sense, CJC-1295 refers to the modified GHRH analogue developed with the Drug Affinity Complex. In many catalogues, however, the phrase CJC-1295 without DAC is used for shorter-acting modified GRF (1-29). That convention is common, but it is chemically loose.

For research comparison, the presence or absence of DAC is not a minor label detail. It changes the study design, sampling windows, expected duration of activity, and the way GH or IGF-1 response is interpreted.

Label often seen in cataloguesBetter descriptionMain research implicationCJC-1295 with DACModified GRF (1-29) with Drug Affinity ComplexLong-lasting albumin binding, sustained GHRH activityCJC-1295 DACShorthand for CJC-1295 with Drug Affinity ComplexUsed where prolonged GH stimulation is the study targetCJC-1295 without DACUsually modified GRF (1-29), often called Mod GRF 1-29Shorter activity profile, more pulse-like research useSermorelinGHRH (1-29) analogue without the DAC extensionShorter-acting GHRH pathway reference compound

A lab comparing these materials should verify the exact identity on the certificate of analysis rather than relying on the listing title. The words with DAC should correspond to the albumin-binding CJC-1295 structure, not merely to a marketing description.

Looking to compare CJC-1295 with DAC prices? Our price comparison hub puts the listings in one place: PeptideSupermarket®’s peptide price comparison page

Why does DAC change the growth hormone release profile?

Natural GHRH signalling is brief and tightly regulated. GHRH is part of the body’s normal pulsatile growth hormone system, acting against the counter-regulatory influence of somatostatin. Short half-life is part of that biology. A short-acting GHRH analogue tends to produce a narrower stimulation window.

The DAC changes that by extending the time over which the GHRH analogue remains present. This is why CJC-1295 DAC is associated with sustained GH release in research descriptions. Longer exposure can also influence IGF-1, because IGF-1 is a downstream marker of GH activity, largely mediated through hepatic and tissue responses.

For experimental planning, this distinction is not academic. A short-acting analogue is usually assessed with close time-point sampling around acute response. A long-acting analogue requires a wider observation window. Researchers looking at GH pulses, IGF-1 changes, tissue repair markers, substrate metabolism, or body composition proxies should not borrow assumptions from one compound and apply them to the other.

What did published CJC-1295 with DAC research find?

The best-known human pharmacology paper is the 2006 Journal of Clinical Endocrinology and Metabolism study by Teichman and colleagues. It examined CJC-1295 as a long-acting GHRH analogue in healthy adults and reported prolonged stimulation of growth hormone and IGF-1 secretion after exposure. That study is the key reason CJC-1295 DAC is still discussed as a sustained GHRH research compound rather than merely another short GHRH fragment.

The paper is useful, but it should not be stretched beyond its purpose. It was a controlled pharmacology study, not a licence to infer real-world body recomposition, anti-ageing, injury recovery, or wellness outcomes. It measured endocrine response. Claims about increased lean muscle mass, enhanced fat loss, improved recovery and tissue repair, boosted energy, or vitality should be treated as research endpoints linked to GH and IGF-1 biology, not as confirmed outcomes for unregulated use.

Earlier peptide endocrinology work also helps explain why the modifications matter. Native GHRH is rapidly degraded, including by cleavage mechanisms that reduce biological activity. Modified GHRH analogues were developed to resist rapid breakdown and improve activity. The DAC strategy takes that idea further by extending exposure through albumin binding.

What are the main research uses of CJC-1295 DAC?

CJC-1295 with DAC is mainly used in research models concerned with growth hormone stimulation and downstream endocrine signalling. The peptide is not simply a general performance compound in credible scientific framing. Its relevance sits in the GHRH, GH, and IGF-1 axis.

Common research themes include:

  • Sustained GH release: The defining DAC-related endpoint, usually assessed through growth hormone response and IGF-1 changes.

  • Lean tissue markers: GH and IGF-1 are involved in protein turnover, which is why lean mass questions appear in research discussions.

  • Fat metabolism endpoints: Growth hormone has recognised effects on lipolysis and substrate use, so fat loss claims are usually tied to mechanistic interest rather than direct proof.

  • Recovery and tissue repair models: IGF-1 signalling intersects with tissue remodelling pathways, making recovery markers a common research angle.

  • Energy and vitality measures: These terms are common in commercial descriptions, but in research they need objective measures such as endocrine markers, sleep architecture, activity data, or validated questionnaires.

The strongest position is to keep the claims narrow. CJC-1295 DAC is a long-acting GHRH analogue for investigating sustained GH axis activation. Anything beyond that needs a defined model, a measurable endpoint, and a source that supports the claim.

CJC-1295 DAC vs sermorelin and ipamorelin: what is the difference?

CJC-1295 DAC is often discussed alongside sermorelin and ipamorelin because all three sit near the GH stimulation category. They are not the same type of compound. Sermorelin is a GHRH analogue. Ipamorelin is a growth hormone secretagogue receptor agonist, often grouped with ghrelin mimetics. CJC-1295 with DAC is a long-acting modified GHRH analogue with albumin binding.

That means a comparison should start with mechanism, not with claimed outcomes.

Compound Main pathway Duration concept Best research fit CJC-1295 with DACG HRH receptor pathway Long-lasting due to Drug Affinity Complex albumin binding Sustained GH and IGF-1 response studies Sermorelin GHRH receptor pathwayShorter-acting GHRH analogue Acute GHRH response and pituitary stimulation models Ipamorelin Growth hormone secretagogue receptor pathwaySecretagogue-style stimulation profileGhrelin receptor related GH release studies

Some studies combine GHRH analogues with GH secretagogues to examine additive or complementary signalling. That is a research design question, not a consumer instruction. Combination work needs controls, validated assays, and clear ethics approval in any living-system model.

How should researchers read a CJC-1295 DAC product listing?

A CJC-1295 with DAC listing should make the identity clear. The phrase with DAC should refer to Modified Growth Hormone Releasing Factor (1-29) with the Drug Affinity Complex, not to a generic peptide blend. A serious comparison should also look for purity testing, mass confirmation, lot-specific documentation, and clear research-only labelling.

Researchers comparing suppliers through a site such as this one should pay attention to:

  • Compound name: It should state CJC-1295 with DAC or Modified GRF (1-29) with Drug Affinity Complex.

  • Testing evidence: Look for batch-specific analytical data rather than a generic purity claim.

  • Storage and handling information: Peptides are sensitive materials, and handling conditions can affect experimental reliability.

  • Regulatory wording: Research peptides should be labelled for in-vitro laboratory research only, not for human or animal use.

  • Listing consistency: Be cautious where a page alternates between CJC-1295 with DAC and without DAC as if they are identical.

CJC-1295 with DAC

Frequently asked questions

What does DAC mean in CJC-1295?

DAC means Drug Affinity Complex. In CJC-1295, it is the albumin-binding modification that gives the peptide a longer-lasting research profile compared with shorter-acting GHRH analogues.

Is CJC-1295 with DAC better than without DAC?

It depends on the research question. CJC-1295 with DAC is better suited to sustained GH and IGF-1 response studies. Modified GRF (1-29), often sold as CJC-1295 without DAC, is more appropriate where a shorter pulse-like GHRH signal is being investigated.

Is CJC-1295 DAC the same as sermorelin?

No. Both act through the GHRH pathway, but CJC-1295 DAC is engineered for long-lasting albumin binding. Sermorelin is a shorter-acting GHRH (1-29) analogue.

What is CJC-1295 DAC used for in research?

It is used in research on growth hormone stimulation, sustained GH release, IGF-1 response, and related endpoints such as lean tissue markers, fat metabolism, recovery biology, and tissue repair signalling.

Is CJC-1295 DAC approved for human use?

CJC-1295 DAC is not presented here as an approved medicine or a product for self-administration. On this site, it is discussed strictly as a research peptide for in-vitro laboratory comparison.

Does DAC make CJC-1295 safer?

DAC changes duration of activity. It should not be read as a safety feature. Longer exposure can make study design more complex because endocrine effects may persist beyond the short sampling window used for non-DAC peptides.

What is the research-only disclaimer?

This article is for research and educational purposes only. It is not medical advice, it does not recommend human or animal use, and it should not be used to guide dosing, treatment, or self-experimentation.

Any work involving peptide materials should follow applicable South African law, institutional rules, laboratory safety standards, and ethics requirements. Endocrine-axis compounds deserve particular care because GH and IGF-1 signalling interacts with many biological systems.

References

Price Comparison

Compare CJC-1295 with DAC prices across the UK

Side-by-side prices from every trusted UK supplier stocking CJC-1295 with DAC.

Compare prices

Get Peptide Price-drop Alerts

Be the first to know when prices drop on your favourite peptides

No spam. Unsubscribe anytime. We respect your privacy.